Group 1 - The core point of the article is that Sangfor Technologies (01530.HK) has entered into a placement agreement with Morgan Stanley to issue approximately 105 million shares at a price of HKD 29.62 per share, representing about 4.32% of the total issued shares as of the announcement date [1] - The estimated total proceeds from the placement are approximately HKD 3.115 billion, with a net amount of about HKD 3.087 billion [2] Group 2 - The company plans to use approximately 80% of the net proceeds for research and development expenses, which includes advancing clinical studies for innovative drugs in China and the U.S., supporting the expansion of indications for commercialized drugs, and building global infrastructure [2] - The remaining 20% of the net proceeds will be allocated for working capital and other general corporate purposes to support the company's ongoing operations and strategic plans [2]
三生制药(01530.HK)拟配售1.05亿股总筹31.15亿港元 加速创新药管线开发与深化商业化布局